MET and cancer: In addition, mutations of TP53, p16INK4a, and overexpression of cyclin D1 and MET were regarded as poor predictors of survival and cancer progression in HNSCC patients (Bova et al., 1999; Muzio et al., 2006; Poeta et al., 2007).